Clifton Park, NY, United States of America

John Richard Nelson

This inventor holds 86 USPTO granted patents and 32 published patent applications, plus 18 CIPO patents and 37 EPO patents, primarily in Nucleic Acid Technologies (CPC class C12Q1-6844). Top assignees: General Electric Company, Ge Healthcare Bio-Sciences Corp., Global Life Sciences Solutions Operations UK Ltd. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Richard Nelson. Retrieved from https://idiyas.com/inventor/john-richard-nelson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 86 (Patent Applications = 32)

% Patents Active = 93.0

CIPO Patents = 18 (Patent Applications = 2)

EPO Patents = 37 (Patent Applications = 32)

Average Co-Inventor Count = 4.1

ph-index = 14

Forward Citations = 758(Granted Patents)

Forward Citations (Not Self Cited) = 697(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Hillsborough, NJ (US) (2006 - 2009)
Cifton Park, NY (US) (2015)
Schenectady, NY (US) (2017)
Redlands, CA (US) (2010 - 2020)
San Diego, CA (US) (2017 - 2021)
Clifton Park, NY (US) (2008 - 2023)
Clifton, NY (US) (2023)
Niskayuna, NY (US) (2018 - 2024)

Company Filing History:

53 out of 52,387

General Electric Company

patents

12 out of 135

Ge Healthcare Bio-Sciences Corp.

patents

7 out of 31

Global Life Sciences Solutions Operations UK Ltd

Global Life Sciences Solutions USA LLC

Ce Healthcare Bio-Sciences Corp.

where one patent can have more than one assignee

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

Nucleic Acid Analysis

Protein Expression

Biomolecule Detection

Electrospun Fibers

Isothermal Amplification

DNA Modification

RNA Amplification

Microbial Metabolism

Sperm Nucleic Acids

Farnesoid X Receptors

Contamination-Free Reagents

Rapid Detection

86 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595501 - EXPRESSION OF PRODUCTS FROM NUCLEIC ACID CONCATEMERS (2026-04-07),

2. 12150984 - Dysregulation of trauma regulation pathway treatment and monitoring techniques (2024-11-26),

3. 11987836 - Method for nucleic acid analysis directly from an unpurified biological sample (2024-05-21),

4. 11834670 - Site-specific DNA modification using a donor DNA repair template having tandem repeat sequences (2023-12-05),

5. 11726078 - Device for rapid detection of tuberculosis-lipoarabinomannan (TB-LAM) with enhanced sensitivity (2023-08-15),

6. 11714084 - Method and associated device for rapid detection of target biomolecules with enhanced sensitivity (2023-08-01),

7. 11555215 - Electrospun fibers for protein stabilization and storage (2023-01-17),

8. 11421259 - Cell-free protein expression using rolling circle amplification product (2022-08-23),

9. 11268116 - Endonuclase-assisted isothermal amplification using contamination-free reagents (2022-03-08),

10. 11142758 - Method and device for collection and amplification of circulating nucleic acids (2021-10-12),

11. 11033859 - Methods for electroelution of biomolecules (2021-06-15),

12. 11021446 - Compositions and methods for modulating farnesoid X receptors (2021-06-01),

13. 11001868 - Cell-free protein expression using double-stranded concatameric DNA (2021-05-11),

14. 10870845 - Methods for capturing nucleic acids (2020-12-22),

15. 10837962 - Method and associated device for rapid detection of target biomolecules with enhanced sensitivity (2020-11-17),

Title: Innovations by John Richard Nelson: A Glimpse into His Patented Work

Introduction

John Richard Nelson, based in Clifton Park, NY, has made significant contributions to the field of biotechnology and medical devices, evidenced by his impressive portfolio of 75 patents. His work often addresses critical health challenges and showcases the transformative potential of modern scientific research.

Latest Patents

Among his latest innovations, Nelson has developed techniques targeting the dysregulation of the trauma regulation pathway. This patent addresses physiological conditions, such as SARS-CoV-2 viral infections, by focusing on methods that utilize renin-angiotensin and splenic pathway molecules for targeted neuromodulation. This cutting-edge approach aims to enhance immune system regulation, serving as an energy-based adjuvant for vaccines.

Another significant patent involves a method for nucleic acid analysis directly from unpurified biological samples. This innovative method allows for the generation of single-stranded DNA circles without the need for intermediate nucleic acid purification. By employing a novel extraction technique, this method not only simplifies the analysis process but also has implications for future biological research and applications.

Career Highlights

Throughout his career, John Richard Nelson has worked with major companies such as General Electric Company and GE Healthcare Bio-sciences Corp. His experience in these leading organizations speaks to his expertise and the high value of his contributions to the field.

Collaborations

Nelson has had the opportunity to collaborate with notable professionals, including Robert Scott Duthie and Gregory Andrew Grossmann. Their collective efforts have undoubtedly propelled the advancements in the projects they have undertaken together, further enriching the innovations in their respective fields.

Conclusion

John Richard Nelson represents an exemplary figure in the realm of inventors, tirelessly advancing medical and biotechnological solutions. His recent patents illustrate a commitment to addressing complex health issues and reflect the future of innovative healthcare solutions. As he continues his work, the potential for further groundbreaking contributions remains vast.

Profile summary based on public USPTO records.